M. Laughlin

发表

R. Bukowski, D. Cutler, P. Statkevich, 2002, Cancer.

Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study.

C. Rouzioux, G. Chêne, J. Molina, 2001, AIDS.

Interferon alfa‐2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics

Steven R. Martin, G. Mieli-Vergani, M. Jonas, 2005, Hepatology.

A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

E. Schiff, J. Hoefs, J. Albrecht, 2001, Hepatology.

A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

E. Schiff, J. Hoefs, J. Albrecht, 2001, Hepatology.

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Tom Chu, Peter W Angus, P. Angus, 2010, The Lancet.

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

M. Silva, D. Cutler, M. Grace, 2006, Journal of hepatology.

749 EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)

R. Elston, P. Angus, C. Stedman, 2010 .

Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.

G. Dusheiko, Y. Lurie, G. Webster, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN

T. Asselah, P. Marcellin, L. Essioux, 2010 .

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

S. Swan, W. Smith, T. Marbury, 2005, Journal of clinical pharmacology.

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

M. Silva, D. Cutler, M. Grace, 2006, Journal of hepatology.